TGTX250117C28500
- 1.61
- +0.56+53.33%
TG Therapeutics Newsroom
TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
TG Therapeutics Is Maintained at Overweight by JP Morgan
TG Therapeutics Analyst Ratings
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
TG Therapeutics Price Target Raised to $55.00/Share From $49.00 by HC Wainwright & Co.
TG Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $22
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
TG Therapeutics: Promising Growth Trajectory and Blockbuster Potential Justify Buy Rating
TD Cowen Initiates TG Therapeutics(TGTX.US) With Buy Rating, Announces Target Price $50
TD Cowen Initiates TG Therapeutics at Buy With $50 Price Target
TG Therapeutics Analyst Ratings
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $38